You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A2A receptor blockade for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARY Sepsis is a clinical syndrome that complicates severe infectionSepsis remains the leading cause of morbidity and mortality in critically ill patientsThere are no specific FDA approved medicines for the treatment of sepsisCurrent concepts of the pathophysiology of sepsis suggest that organ failure and mortality in sepsis are caused by inappropriate regulation of the immune systemThis manife ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. A2B receptor stimulation for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARYSepsis is a medical condition caused by an overwhelming systemic inflammatory response to infection. Although the underlying infection can now be efficiently treated with antibiotics, there are no effective therapies to control the organ damage caused by the inflammatory response of the host. As a result, sepsis is the leading cause of mortality in intensive care units and is the tenth lead ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. AC5 Inhibitor for Obesity

    SBC: VASADE BIOSCIENCES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a drug that will be therapeutic for obesity and diabetes and improve exercise tolerance. Obesity, diabetes and exercise are inextricably linked such that an agent that improves exercise tolerance or prevents obesity or the development of diabetes will likely have a therapeutic role in all three conditions. Obesity is a gl ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Acne Vaccines Targeting a Surface Sialidase and a Secreted CAMP Factor Toxin

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Propionibacterium acnes (P. acnes) is most notably recognized for its role in acne vulgaris, the most common skin disease, affecting 85-100% of the population at some point in their lives. Current treatments for vulgari s acne using isotretinoin (13-cis-retinoic acid) or antibiotics can have many undesirable effects, including depression, teratogenicity, hormon ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Reliable diagnostic differentiation between acute and chronic myocardial infarcts would be of great benefit for cardiac surgeons and interventional cardiologists. Such differentiation could be used to make decisions about which vessels and in what order would be reopened or bypassed. MRI is an intrinsically noninvasive diagnostic tool and the Delayed Enhancemen ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Adenovirus vectored vaccines for Alzheimer's disease

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common neurodegenerative disease in the elderly. To date, no satisfactory treatment is available for AD. One of the pathological hallmarks of AD is deposits of amyloid protein (Aa) in neuritic plaques and cerebral vessels. Increasing lines of evidence support the notion that Aa and its precursor (APP) play pathogenetic roles i ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  8. A device containing an immobilized chelator to remove aluminum from total parente

    SBC: ALKYMOS, INC            Topic: NICHD

    DESCRIPTION (provided by applicant): A high percentage of the ~ 500,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common contam ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. A device containing immobilized chelator to remove aluminum from TPN solutions

    SBC: ALKYMOS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): A high percentage of the ~ 470,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common conta ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Advanced Absorbance Detection for the AUC

    SBC: AVIV BIOMEDICAL INC            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this STTR is to produce a commercially available rapid-scan absorbance optical detection system for XLA/I analytical ultracentrifuges. The currently available absorbance optical system provided by the analytical ultracentrifuge manufacturer is not optimized for sedimentation velocity analysis, the most commonly used analytical ultracentrifugation ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government